Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Accenture
Fish and Richardson
AstraZeneca
Cipla
Express Scripts
Argus Health
UBS
Harvard Business School
Merck

Generated: August 23, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title: Polypeptides, processes for their production, pharmaceutical compositions comprising said polypeptides and their use
Abstract:Straight-chain and mono-cyclic polypeptides containing the basic sequence ##STR1## wherein X is an amino acid residue, the residues in the 1- and 6-positions being linked by an --S--S-- bridge when the polypeptide is monocyclic, have pharmacological, in particular GH--, gastric- and pancreatic-secretion inhibiting activity.
Inventor(s): Bauer; Wilfried (Lampenberg, CH), Pless; Janos (Basel, CH)
Assignee: Sandoz Ltd. (Basel, CH)
Application Number:06/321,663
Patent Claims: 1. A polypeptide of formula (I) ##STR39## wherein A is C.sub.1-12 alkyl, C.sub.7-10 phenylalkyl or a group of formula RCO--, whereby

(i) R is hydrogen, C.sub.1-11 alkyl, phenyl or

C.sub.7-10 phenylalkyl, or

(ii) RCO-- is

(a) an L- or D-phenylalanine residue optionally ring-substituted by halogen, NO.sub.2, NH.sub.2, OH, C.sub.1-3 alkyl and/or C.sub.1-3 alkoxy

(b) --Asn-- or the residue of a natural .alpha.-amino acid having a hydrocarbyl side chain other than defined under (a) above or of a corresponding D-amino acid, or

(c) a dipeptide residue in which the individual amino acid residues are the same or different and are selected from those defined under (a) and/or (b) above, the .alpha.-amino group of amino acid residues (a) and (b) and the N-terminal amino group of dipeptide residues (c) being optionally mono- or di-C.sub.1-12 alkylated,

A' is hydrogen or, when A is C.sub.1-12 alkyl or C.sub.7-10 phenylalkyl, also C.sub.1-12 alkyl or C.sub.7-10 phenylalkyl,

B is --Phe-- optionally ring-substituted by halogen, NO.sub.2, NH.sub.2, OH, C.sub.1-3 alkyl and/or C.sub.1-3 alkoxy,

C is --(L)-- or --(D)--Trp-- optionally .alpha.-N-methylated and optionally benzene-ring-substituted by halogen, NO.sub.2, NH.sub.2, OH, C.sub.1-3 alkyl and/or C.sub.1-3 alkoxy,

D is --Lys-- optionally .alpha.-N-methylated and optionally .epsilon.-N-C.sub.1-3 alkylated,

E is --Thr-- or --Ala-- each in (D)- or (L)- form and each being optionally .alpha.-N-methylated,

F is a group of formula ##STR40## wherein R.sub.1 is hydrogen or C.sub.1-3 alkyl,

R.sub.2 is hydrogen or the residue of a physiologically acceptable, physiologically hydrolysable ester,

R.sub.3 is hydrogen, C.sub.1-3 alkyl, phenyl, benzyl or C.sub.9-10 phenylalkyl,

R.sub.4 is hydrogen, C.sub.1-3 alkyl or, when R.sub.3 is hydrogen or methyl, also a group of formula --CH(R.sub.5)--X wherein

R.sub.5 is hydrogen, --(CH.sub.2).sub.2 --OH, --(CH.sub.2).sub.3 --OH, --CH.sub.2 --OH, --CH(CH.sub.3)--OH, isobutyl or benzyl and

X is a group of formula ##STR41## wherein R.sub.1 and R.sub.2 have the meanings given above,

R.sub.6 is hydrogen or C.sub.1-3 alkyl and

R.sub.7 is hydrogen, C.sub.1-3 alkyl, phenyl or C.sub.7-10 phenylalkyl, the group --CH(R.sub.5)--X having the D- or L-configuration, and

Y.sub.1 and Y.sub.2 are each hydrogen or together represent a direct bond,

whereby the residues in the 1- and 6-position each independently have the L- or D-configuration,

with the proviso (i) that D- and/or L-cysteine residues are present at the 1- and 6-positions only, and (ii) that when R.sub.5 is benzyl, X is a group of formula ##STR42## or a group of formula --COOR.sub.1, wherein R.sub.1 is C.sub.1-3 alkyl, or a pharmaceutically acceptable acid addition salt or complex thereof.

2. A compound according to claim 1, wherein R.sub.3 is hydrogen, C.sub.1-3 alkyl or phenyl.

3. A compound according to claim 1, wherein, when R.sub.5 is benzyl, X is a group of formula ##STR43##

4. A compound according to claim 1, wherein

R.sub.3 is hydrogen or methyl and

R.sub.4 is a group of formula --CH(R.sub.5)--X.

5. A compound according to claim 3, wherein

R.sub.3 is hydrogen or methyl and

R.sub.4 is a group of formula --CH(R.sub.5)--X.

6. A compound according to claim 1, wherein

A is a group of formula RCO--, whereby

(i) R is C.sub.1-11 alkyl or C.sub.7-10 phenylalkyl, or

(ii) RCO-- is

(a) an L- or D-N-(C.sub.1-8 alkyl)-phenylalanine residue, or

(b) a leucine or nor-leucine residue, said residues having the L- or D-configuration,

A' is hydrogen, and

F is a group of formula ##STR44##

7. A compound according to claim 6, wherein

F is a group of formula ##STR45## wherein R.sub.3 is hydrogen or methyl,

R.sub.5 is --CH.sub.2 OH, --CH(CH.sub.3)--OH, isobutyl, benzyl --(CH.sub.2).sub.2 --OH or --(CH.sub.2).sub.3 --OH, and

X is a group of formula ##STR46## or a group of formula --CH.sub.2 --OR.sub.2, wherein R.sub.2 is hydrogen, HCO, C.sub.2-12 alkylcarbonyl, C.sub.8-12 phenylalkylcarbonyl or benzoyl.

8. A compound according to claim 1, wherein

B is --Phe--,

C is --(D)Trp--,

D is --Lys--, --MeLys-- or --Lys(.epsilon.--Me)--, and

E is --Thr--.

9. A compound according to claim 6, wherein

B is --Phe--,

C is --(D)Trp--,

D is --Lys--, --MeLys-- or --Lys(.epsilon.--Me)--, and

E is --Thr--.

10. A compound according to claim 1, wherein X is a group of formula --CH.sub.2 OR.sub.2.

11. A compound according to claim 7, wherein X is a group of formula --CH.sub.2 OR.sub.2.

12. A polypeptide according to claim 1, wherein

A is C.sub.1-3 alkyl, C.sub.7-10 phenylalkyl or a group of formula RCO--,

A' is hydrogen,

R is hydrogen, C.sub.1-3 alkyl, phenyl or C.sub.7-10 phenylalkyl or

RCO is

(a) an L- or D-phenylalanine residue optionally mono-ring-substituted by halogen, NO.sub.2, NH.sub.2, OH, C.sub.1-3 alkyl or C.sub.1-3 alkoxy, or

(b) the residue of a natural .alpha.-amino acid having a hydrocarbyl side chain other than defined under (a) above or of a corresponding D-amino acid, the amino group of amino acid residues (a) and (b) being optionally mono-C.sub.1-3 alkylated,

F is a group of formula ##STR47## R.sub.2 is hydrogen, R.sub.3 is hydrogen or C.sub.1-3 alkyl,

R.sub.7 is hydrogen or C.sub.1-3 alkyl and

Y.sub.1 and Y.sub.2 together represent a direct bond,

and B, C, D, E, R.sub.1, R.sub.4, R.sub.5, R.sub.6 and X have the meanings given above in claim 1, as well as the acid addition salts and complexes thereof.

13. A polypeptide according to claim 1 of formula ##STR48## or a salt form or a complex thereof.

14. A polypeptide according to claim 1 of formula ##STR49## or a salt form or a complex thereof.

15. A compound according to claim 1 selected from the group consisting of ##STR50## (u) H--(D)Phe--Cys--Phe--(D)Trp--Lys--Thr--Cys--Thr--ol or a pharmaceutically acceptable acid addition salt or complex thereof.

16. A compound according to claim 1 of the formula ##STR51## wherein A is RCO-- and

R is C.sub.7-10 phenalkyl or

RCO is H--(D)Phe-- or H--(D)MePhe--, optionally ring substituted by halo; H--Nle--, H--Asn-- or H--Nle--Asn--;

B is Phe, optionally ring substituted by halo;

E is --Thr--, --(D)Thr-- or --(D)Ala--; and

F is ##STR52## where R.sub.3 is hydrogen;

R.sub.5 is --(CH.sub.2).sub.2 --OH, --CH.sub.2 --OH, --CH(CH.sub.3)--OH, isobutyl or benzyl; and

X is --CONH.sub.2 or --CH.sub.2 OR.sub.2

where

R.sub.2 is hydrogen or a physiologically acceptable, physiologically hydrolysable ester thereof and

Y.sub.1 and Y.sub.2 are each hydrogen or together are a direct bond,

wherein the amino acid residues represented by F and in the 1- and 6-position each independently have the L- or D-configuration or

a pharmaceutically acceptable acid addition salt or complex thereof.

17. A compound according to claim 1 having the structure ##STR53## selected from the group in which A, E and F are respectively (a) H--(D)Phe--, --Thr--, and --(D)Ser--NH.sub.2 ;

(b) H--(D)Phe--, --Thr--, and --NH.sub.2 ;

(c) H--(D)Phe--, --Thr--, and --Phe--ol;

(d) H--(D)Phe--, --Thr--, and --Asp--diol;

(e) H--Nle--, --Thr--, and --(D)Ser--NH.sub.2 ;

(f) H--(D)Phe--, --(D)Ala--, and --(D)Ser--NH.sub.2 ;

(g) H--Asn--, --Thr--, and --(D)Ser--NH.sub.2 ;

(h) H--(D)MePhe--, --Thr--, and --Thr--ol;

(i) H--Nle--Asn--, --Thr--, and --Thr--ol;

(j) H--(D)Phe--, --(D)Ala--, and --Thr--ol;

(k) H--(D)Phe--, --Thr--, and --Ser--ol;

(l) H--(D)Phe--, --(D)Thr--, and --Thr--ol; ##STR54## (n) H--(D)Phe(pF)--, --Thr--, and --Thr--ol; or a pharmaceutically acceptable acid addition salt or complex thereof.

18. A compound according to claim 1 in which E is --(L) or --(D)Thr-- or --(D)Ala--.

19. A method of treating disorders with an aetiology comprising or associated with excess GH-secretion in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a polypeptide as claimed in claim 1 or of a pharmaceutically acceptable salt form or complex thereof.

20. A method of treating gastro-intestinal disorders in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a polypeptide as claimed in claim 1 or of a pharmaceutically acceptable salt form or complex thereof.

21. A pharmaceutical composition useful in the treatment of excess GH-secretion or gastro-intestinal disorders comprising a polypeptide as claimed in claim 1 or a pharmaceutically acceptable salt form or complex thereof together with a pharmaceutically acceptable diluent or carrier therefor.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
Teva
Colorcon
Dow
Citi
Baxter
Farmers Insurance
UBS
Medtronic
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot